<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248427</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI1402</org_study_id>
    <nct_id>NCT03248427</nct_id>
  </id_info>
  <brief_title>Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.</brief_title>
  <acronym>CORALLEEN</acronym>
  <official_title>CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CORALLEEN is a two-arm, randomized, multicentric study in postmenopausal women with primary&#xD;
      HR+/HER2 negative Luminal B breast cancer that will explore if the combination of ribociclib&#xD;
      with letrozole offers clinical benefit at least comparable to that of standard chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel, two-arm, randomized 1:1, stratified by tumor size and nodal involvement,&#xD;
      open-label, multicenter, exploratory study in postmenopausal women with primary operable&#xD;
      HR+/HER2-negative Luminal B breast cancer according to PAM50 intrinsic subtype to evaluate&#xD;
      the clinical benefit and biological effects of ribociclib combined with letrozole.&#xD;
&#xD;
      The primary trial objective is to evaluate the ability of each treatment strategy to provide&#xD;
      ROR-low score at surgery.&#xD;
&#xD;
      Luminal B patients will be randomized 1:1 to either letrozole plus ribociclib or&#xD;
      chemotherapy.Two weeks after the first administration of the assigned treatment, patients&#xD;
      will undergo a biopsy to assess early biological response to treatment, at Ki67 protein and&#xD;
      gene expression level. After finalization of the assigned neoadjuvant treatment, patients&#xD;
      will undergo surgery.&#xD;
&#xD;
      The primary endpoint, Rate of ROR-low (at surgery) after neoadjuvant treatment, according to&#xD;
      the Prosigna test will be centrally assessed.&#xD;
&#xD;
      Baseline, Day 15 and post-treatment (surgical) primary breast tumor tissue samples should be&#xD;
      available for each patient for molecular characterization A post-surgery visit will be&#xD;
      performed within 28 days (7 days) from surgery, and will mark the end of the study for that&#xD;
      patient&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2017</start_date>
  <completion_date type="Actual">July 20, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of ROR-low according to the Prosigna test.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of ROR-low after neoadjuvant treatment at surgery, according to the Prosigna test,as per central assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Overall response rate (ORR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Tumor overall objective response rate (ORR), defined as the sum of Partial Responses (PR) and Complete Responses (CR) according to RECIST v1.1, as per Investigator's assessments by breast MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR in the breast and axillary lymph nodes</measure>
    <time_frame>24 weeks</time_frame>
    <description>pCR is defined as the complete absence of invasive carcinoma in the breast and axillary lymph nodes on histological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEPI Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Preoperative endocrine prognostic index (PEPI) score in the ribociclib plus letrozole treatment arm compared to historical values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Cancer Burden (RCB)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of residual cancer burden (RCB) score 0 or 1 (RCB0/1) after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per central assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast conserving surgery (BCS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of breast conserving surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Ki67 in both treatment arms.</measure>
    <time_frame>At baseline, in week 2, and pre-surgery</time_frame>
    <description>Decrease in Ki67 in both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, duration and severity of Adverse Events (AEs)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Incidence, duration and severity of Adverse Events (AEs) assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ribociclib + Letrozol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.</description>
    <arm_group_label>Ribociclib + Letrozol</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5mg</intervention_name>
    <description>Daily continuous</description>
    <arm_group_label>Ribociclib + Letrozol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60 mg/m2 as a continuous IV perfusion</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 MG/M2 in a 30 minutes IV infusion</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m2, in one hour IV infusion</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Signed Informed Consent Form prior to any study-specific procedure.&#xD;
&#xD;
          2. Female patients.&#xD;
&#xD;
          3. Post-menopausal status and age ≥18 years.&#xD;
&#xD;
          4. Histologically confirmed invasive breast carcinoma, with all the following&#xD;
             characteristics:&#xD;
&#xD;
               -  Primary tumor ≥ 2cm in largest diameter as measured by breast MRI&#xD;
&#xD;
               -  Stage I to stage IIIA breast cancer&#xD;
&#xD;
               -  No evidence of distant metastasis (M0)&#xD;
&#xD;
          5. Breast cancer eligible for primary surgery.&#xD;
&#xD;
          6. Available pre-treatment FFPE core (Tru-cut) biopsy evaluable for PAM50 or possibility&#xD;
             to obtain one. Minimal sample requirements are to have at least 2 tumor cylinders with&#xD;
             a minimal tissue surface of 10 mm2 tissue, containing at least 10% tumor cells and&#xD;
             having enough tissue to do at least 2 cuts of 10 micrometers each.&#xD;
&#xD;
          7. Luminal B subtype as per PAM50 analysis of pre-treatment sample.&#xD;
&#xD;
          8. ER-positive and/or PgR-positive and HER2-negative tumor by ASCO/CAP guidelines&#xD;
             assessed locally.&#xD;
&#xD;
          9. In the case of a multifocal tumor (defined as the presence of two or more foci of&#xD;
             cancer within the same breast quadrant), the largest lesion must be ≥ 2 cm and&#xD;
             designated the &quot;target&quot; lesion for all subsequent tumor evaluations and&#xD;
             HR+/HER2-negative status must be documented in all the tumor foci.&#xD;
&#xD;
         10. ECOG performance status of 0 or 1.&#xD;
&#xD;
         11. Adequate hematological, renal and hepatic function.&#xD;
&#xD;
         12. Ability and willingness to comply with study visits, treatment, testing and to comply&#xD;
             with the protocol.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Any prior treatment for primary invasive breast cancer.&#xD;
&#xD;
          2. Inoperable locally advanced or inflammatory (i.e., inoperable Stage III) breast&#xD;
             cancer.&#xD;
&#xD;
          3. Metastatic (Stage IV) breast cancer.&#xD;
&#xD;
          4. Bilateral invasive breast cancer.&#xD;
&#xD;
          5. Multicentric breast cancer, defined as the presence of two or more foci of cancer in&#xD;
             different quadrants of the same breast.&#xD;
&#xD;
          6. Patients who have undergone sentinel lymph node biopsy prior to study treatment.&#xD;
&#xD;
          7. Inability or unwillingness to swallow pills.&#xD;
&#xD;
          8. Malabsorption syndrome or other condition that would interfere with enteric absorption&#xD;
             of study drugs.&#xD;
&#xD;
          9. Participation in a prior investigational study within 30 days prior to enrollment or&#xD;
             within 5 half-lives of the investigational product, whichever is longer.&#xD;
&#xD;
         10. Patient with a Child-Pugh score B or C.&#xD;
&#xD;
         11. Patient has active cardiac disease or a history of cardiac dysfunction including any&#xD;
             of the following:&#xD;
&#xD;
               -  History of acute coronary syndromes (including myocardial infarction, unstable&#xD;
                  angina, coronary artery bypass grafting, coronary angioplasty or stenting) or&#xD;
                  symptomatic pericarditis within 12 months prior to screening.&#xD;
&#xD;
               -  History of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV).&#xD;
&#xD;
               -  Documented cardiomyopathy.&#xD;
&#xD;
               -  Patient has a Left Ventricular Ejection Fraction (LVEF) &lt; 50% as determined by&#xD;
                  Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).&#xD;
&#xD;
               -  Clinical significant cardiac arrhythmias (e.g. ventricular tachycardia), complete&#xD;
                  left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz&#xD;
                  type II and third-degree AV block)&#xD;
&#xD;
               -  Long QT Syndrome or family history of idiopathic sudden death or congenital long&#xD;
                  QT syndrome.&#xD;
&#xD;
               -  On screening 12-lead ECG, any of the following cardiac parameters (defined as the&#xD;
                  mean of triplicate ECGs: bradycardia (resting heart rate &lt; 50), tachycardia&#xD;
                  (resting heart rate &gt; 90), PR interval &gt; 220 msec, QRS interval &gt;109 msec, or&#xD;
                  QTcF interval ≥450 msec (using Fridericia's correction).&#xD;
&#xD;
         12. Uncontrolled hypertension (Systolic blood pressure &gt;160 mmHg or &lt;90 mmHg and/or&#xD;
             diastolic &gt;100 mmHg).&#xD;
&#xD;
         13. Active infection requiring intravenous (IV) antibiotics.&#xD;
&#xD;
         14. Symptomatic hypercalcemia despite adequate management.&#xD;
&#xD;
         15. Clinically significant history of liver disease, including viral or other hepatitis,&#xD;
             current alcohol abuse, or cirrhosis.&#xD;
&#xD;
         16. Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         17. Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic&#xD;
             dysfunction, physical examination finding, or clinical laboratory finding giving&#xD;
             reasonable suspicion of a disease or condition that contraindicates the use of an&#xD;
             investigational drug, that may compromise compliance with the protocol, that may&#xD;
             affect the interpretation of the results, or renders the patients at high risk from&#xD;
             treatment complications.&#xD;
&#xD;
         18. Significant traumatic injury within 3 weeks prior to initiation of study treatment.&#xD;
&#xD;
         19. Major surgical procedure (not including minor procedures such as lymph node biopsy,&#xD;
             tumor core biopsy, fine needle aspiration) within 4 weeks prior to initiation of study&#xD;
             treatment or not fully recovered from any side effects of previous procedures.&#xD;
&#xD;
         20. Any psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
         21. History of other malignancy within 5 years prior to screening, except for&#xD;
             appropriately treated basal or squamous cell carcinoma, carcinoma in situ of the&#xD;
             cervix, non-melanoma skin carcinoma, or Stage I uterine cancer.&#xD;
&#xD;
         22. Hormone replacement therapy stopped less than 2 weeks before treatment start.&#xD;
&#xD;
         23. Currently receiving or has received systemic corticosteroids until 2 weeks before&#xD;
             treatment start or who have not fully recovered from side effects of such treatment.&#xD;
             Following corticosteroid uses are permitted: single doses, topical applications (e.g.&#xD;
             for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local&#xD;
             injections (e.g. intra-articular)&#xD;
&#xD;
         24. Known hypersensitivity to any of the excipients of ribociclib, letrozole, doxorubicin,&#xD;
             cyclophosphamide or paclitaxel.&#xD;
&#xD;
         25. Patients currently on following medications, which cannot be interrupted 7 days prior&#xD;
             treatment start:&#xD;
&#xD;
               -  Any prohibited medication as per letrozole, doxorubicin, cyclophosphamide, or&#xD;
                  paclitaxel label.&#xD;
&#xD;
               -  Herbal preparations/medications, dietary supplements.&#xD;
&#xD;
               -  Medications that have a known risk to prolong the QT interval or cause Torsades&#xD;
                  de Pointe.&#xD;
&#xD;
               -  Medications with a narrow therapeutic window and predominantly metabolized&#xD;
                  through CYP3A4/5.&#xD;
&#xD;
               -  Strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit&#xD;
                  hybrids, pummelos, star-fruit and Seville oranges.&#xD;
&#xD;
               -  Warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or&#xD;
                  otherwise. Therapy with heparin, low molecular weight heparin or fondaparinux is&#xD;
                  allowed.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleix Prat, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H.Clinic de Barcelona/</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquin Gavilá, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia l'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castelló</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Privada Hospital Asil de Granollers</name>
      <address>
        <city>Granollers</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico MD Anderson International España</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Rey Juan Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación de Alcorcón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de València</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Luminal B tumors</keyword>
  <keyword>Ribociclib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

